ICH E6(R3) Principles and Annex 1 were adopted at Step 4 on January 6, 2025, with typographical corrections October 24, 2025. Annex 2 was adopted June 3, 2026; the consolidated final guideline is dated June 16, 2026. Step 4 is a recommendation for regional adoption, not a worldwide legal effective date. FDA issued final E6(R3) guidance in September 2025; EU implementation of Principles and Annex 1 is July 23, 2025. Do not infer Annex 2 regional implementation from those earlier dates. Device trials remain subject to applicable device law and ISO 14155 where relevant, not a universal E6 mandate.

Why it matters

ICH E6 addresses medicinal-product clinical trials. Device sponsors may use relevant principles, but must assess applicable device investigation requirements and ISO 14155 separately. Regional adoption does not establish a universal mandatory E6 date for devices.

Common pitfalls

•Treating R3 as a minor update, the principles-based structure represents a meaningful shift in how GCP compliance is demonstrated.
•Do not drop existing SOP controls merely because R3 is principles-based; evaluate applicable regional requirements and document justified revisions.
•Assuming regional adoption of Principles and Annex 1 also establishes Annex 2 implementation. Check the regional regulator and the applicable clinical-trial requirements separately.

Sources

ICH E6(R3) Guideline · ICH
FDA Implementation of ICH E6(R3) · FDA
AAMI Standards · AAMI
ICH consolidated final E6(R3), June 2026 · ICH
ICH adoption chronology · ICH
FDA September 2025 final guidance · FDA
EMA E6 implementation · EMA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.